These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17622534)

  • 1. Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis.
    Aksu K; Donmez A; Ertan Y; Keser G; Inal V; Oder G; Tombuloglu M; Kabasakal Y; Doganavsargil E
    Rheumatol Int; 2007 Dec; 28(2):185-7. PubMed ID: 17622534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis.
    Aksu K; Cagirgan S; Ozsan N; Keser G; Sahin F
    Rheumatol Int; 2011 Dec; 31(12):1645-7. PubMed ID: 20013270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of etanercept in ankylosing spondylitis hip lesions.
    Wang D; Ma L; Wu D
    Joint Bone Spine; 2011 Oct; 78(5):531-2. PubMed ID: 21570332
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of genetic predisposition of de novo uveitis with etanercept in ankylosing spondylitis.
    Killian M; Touraine R; Amouzougan A; Thomas T; Marotte H
    Ann Rheum Dis; 2015 Mar; 74(3):e22. PubMed ID: 25467296
    [No Abstract]   [Full Text] [Related]  

  • 7. Etanercept: new indication. For ankylosing spondylitis: another option.
    Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.
    Braun J; van der Horst-Bruinsma IE; Huang F; Burgos-Vargas R; Vlahos B; Koenig AS; Freundlich B
    Arthritis Rheum; 2011 Jun; 63(6):1543-51. PubMed ID: 21630245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid remission of treatment-resistant ankylosing spondylitis with etanercept--a drug for refractory ankylosing spondylitis?
    Barthel HR
    Arthritis Rheum; 2001 Aug; 45(4):404. PubMed ID: 11501730
    [No Abstract]   [Full Text] [Related]  

  • 10. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
    Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of etanercept on iritis in patients with ankylosing spondylitis.
    Rosenbaum JT
    Arthritis Rheum; 2004 Nov; 50(11):3736-7. PubMed ID: 15529379
    [No Abstract]   [Full Text] [Related]  

  • 14. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
    Pfueller CF; Seipelt E; Zipp F; Paul F
    Scand J Rheumatol; 2008; 37(5):397-9. PubMed ID: 18720264
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.
    de Vries MK; van der Horst-Bruinsma IE; Nurmohamed MT; Aarden LA; Stapel SO; Peters MJ; van Denderen JC; Dijkmans BA; Wolbink GJ
    Ann Rheum Dis; 2009 Apr; 68(4):531-5. PubMed ID: 18375542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept.
    van der Heijde D; Landewé R; Einstein S; Ory P; Vosse D; Ni L; Lin SL; Tsuji W; Davis JC
    Arthritis Rheum; 2008 May; 58(5):1324-31. PubMed ID: 18438853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute exacerbation of ankylosing spondylitis after chlamydial infection in a patient well-controlled with etanercept.
    Kim GT
    Int J Rheum Dis; 2012 Oct; 15(5):e113-5. PubMed ID: 23083043
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angioimmunoblastic T cell lymphoma in an ankylosing spondylitis patient treated with etanercept.
    Jung KH; Lim MJ; Kwon SR; Joo KW; Yi HG; Choi SJ; Park W
    Mod Rheumatol; 2013 Jul; 23(4):817-22. PubMed ID: 22791222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment.
    Zou JX; Braun J; Sieper J
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S34-7. PubMed ID: 12463444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.